The commercial landscape for genetic testing has come a long way from testing only for certain inherited genes directly linked to disease, such as BRCA genes whose mutations heighten risk for breast cancer. Myriad Genetics made its name with BRCA testing, but in 2017 the company also began marketing a different type of test, one that turns up multiple genetic variants found throughout a woman’s genome that together may point toward her risk of breast cancer. Earlier this year Ambry Genetics began marketing a similar test to estimate a man’s risk of prostate cancer.

These tests generate polygenic risk scores, gathering multiple genetic variants that together are used to predict someone’s chance of developing a disease. But what are these scores, and how much faith should people put in them?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy